Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

• Status: Terminated
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GE Healthcare
• Collaborator: i3 Statprobe
• Treatments: Flutemetamol

Criteria

Inclusion Criteria:

• The subject is at least 50 years of age.

• The subjects' general health is adequate to comply with study procedures.

• The subject has been scheduled for a shunt placement procedure for the treatment of NPH.

Exclusion Criteria:

• The subject has a contraindication for MRI or PET.

• The subject is pregnant or lactating.

• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.

• The subject has participated in any clinical study using an investigational agent within 30 days of dosing.